Tag: share

CFO Dana Gerner to Retire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES

SEOUL, South Korea, July 08, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading gaming company delivering exceptional player experiences across multiple genres, announced today that the Company entered into a Share Purchase and Transfer Agreement with Azerion Tech Holding B.V. to acquire WHOW Games GmbH, a social casino developer headquartered in Hamburg, Germany. The initial consideration for 100% ownership interest in WHOW Games is €55 million (approximately $64.7 million⁽¹⁾). An additional earn-out payment of up to €10 million, payable to Azerion at €5 million annually, is contingent upon WHOW Games meeting certain performance targets during each of the first and second year following the closing date. The acquisition will be financed through DoubleDown’s cash reserves and is expected to close during the third quarter of 2025.

More Than Doubles H2O America’s Connections in Texas and Increases Exposure to High Growth Houston Region

8 July 2025 - Reference is made to the stock exchange announcement made by Prosafe SE (the "Company") on 16 May 2025 regarding the extraordinary general meeting's resolution to decrease the share capital of the Company by EUR 22,157,127.24, from EUR 22,335,813.75 to EUR 178,686.51, through a decrease of the nominal value of each share in the Company by EUR 1.24, from EUR 1.25 to EUR 0.01.

SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934.